Functional Characterization of a Fluorescent Highly Tumorigenic Ovarian Cancer Line to Test Cellular Therapy in Experimental Models

Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies, and two thirds of patients present with stages III and IV disease. Standard first-line therapy for ovarian cancer includes cytoreductive surgery followed by combination platinum/taxaneYbased chemotherapy and yields impressive response rates of 75% to 80%.1 The addition of intraperitoneal chemotherapies improved median overall sur- vival to E?65 months, representing a significant improvement in the last 20 years.2,3